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INTRODUCTION
Chronic therapy with methotrexate (MTX), a broadly used anti-cancer and anti-rheumatic drug, may protect rheumatic patients against metabolic risk factors associated with cardiovascular disease, obesity (1) and type 2 diabetes (2). This notion is supported by recent observations that MTX alleviates hyperglycemia and insulin resistance in diabetic (db/db) mice (3) and obese mice fed a high-fat diet (4) . MTX is a folate antagonist and inhibits DNA replication (5) , which explains its anti-cancer action, but the not improvements in glucose homeostasis in type 2 diabetes or obesity. Suppression of chronic inflammation, thought to arise from MTX-stimulated adenosine release (6) , may improve glucose homeostasis indirectly (7) . Since anti-rheumatic drugs are not invariably associated with metabolic protection (1, 8) , other mechanisms are likely. While MTX-induced adenosine release may have direct metabolic effects (4), its exact role is ambiguous, since both adenosine receptor activation (9) and blockage (10) improves insulin sensitivity. Clearly the molecular underpinnings of MTX action in relation to metabolic disease remain undefined.
MTX has several pharmacological targets, including 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase / inosine monophosphate cyclohydrolase (ATIC) (11) . ATIC is essential for the conversion of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl-5'-monophosphate (ZMP) to inosine monophosphate in the final two steps of the de novo purine synthesis pathway. Thus, congenital ATIC deficiency or MTX therapy elevates intracellular ZMP content and excretion of its metabolites (6, 12, 13) . The purine precursor ZMP is also an AMP-mimetic and activates the AMP-activated protein kinase (AMPK) (14) . AMPK is a heterotrimeric serine-threonine kinase, composed of the catalytic α and non-catalytic β and γ subunits (15) . ZMP binds to the AMP-binding sites on the γ subunits (16) , and this is required for its ability to activate AMPK (17) . AMPK plays a role in maintaining energy homeostasis and is currently a target for the treatment of type 2 diabetes 4 (18) (19) (20) . Thus, MTX might mitigate metabolic impairments by promoting ZMP-stimulated AMPK activation in key organs controlling glucose homeostasis.
AMPK activation increases glucose uptake, fatty acid oxidation and mitochondrial biogenesis, which helps to ameliorate different aspects of metabolic dysregulation, including hyperglycemia and insulin resistance (19) . MTX could promote ZMP accumulation and AMPK activation by suppressing ATIC, which is expressed and active in skeletal muscle (21, 22) . ZMP is also the active metabolite of the pharmacological AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) (14) . AICAR therapy promotes favorable metabolic reprogramming in skeletal muscle of sedentary (23) and diabetic (ob/ob) mice (24) . However, a relatively high threshold for AMPK activation (25) , in conjunction with poor bioavailability (26) , limits the usefulness of AICAR in the treatment of type 2 diabetes (27) . MTX may enhance AICAR-stimulated AMPK activation in skeletal muscle by suppressing ATIC-mediated ZMP clearance and overcome this problem.
Here, we show that MTX markedly reduces the threshold for AICAR-stimulated AMPK activation and potentiates glucose uptake and lipid oxidation in skeletal muscle. Thus, co-therapy with AICAR and MTX could represent a novel strategy to treat metabolic disorders and overcome current limitations of AICAR mono-therapy.
METHODS

Antibodies and reagents
Antibodies against phospho-AMPKα (Thr 172 ) and phospho-ACC (Ser 79 ) were from Cell Signaling Technology (Beverly, MA), the antibody against ATIC was from Sigma-Aldrich (Stockholm, Sweden), the GLUT4 antibody was from Millipore (Temecula, CA), and the antibody against GAPDH was from Santa Cruz Biotechnology (Santa Cruz, CA). ECL reagent and the protein molecular weight marker were from GE Healthcare (Uppsala, 
Experimental animals
This study was approved by the Regional Animal Ethical Committee (Stockholm, Sweden).
AMPK-γ3 knock-out (AMPK-γ3 -/-) mice were bred onto a C57BL/6 genetic background and have been thoroughly characterized (28) . Prior to all experiments, AMPK-γ3 -/-and wild-type mice were fasted for 4 hours before being anesthetized with Avertin (0.02 ml/g i.p.). Immunoreactive proteins were visualized by enhanced chemiluminiscence and quantified by the Quantity One 1-D Analysis Software (Bio-Rad). Data were normalized to GAPDH.
Metabolic assays in isolated skeletal muscle
Plasmids and generation of stable wild-type and R531G AMPK-γ2 HEK-293 cell lines
Full-length human γ2 was amplified with primers designed to encode a 5'-BamHI site and a C-terminal FLAG tag followed by an XhoI site. (Promega) using the plasmids POG44 and pcDNA5/FRT/TO/g2 at a ratio of 9:1. Fresh medium was added to the cells 24 hours after transfection, and media containing 200 µg/ml hygromycin B and 15 µg/ml blasticidin was added 48 hours after transfection. The medium was replaced every 3 days until foci could be identified, and individual foci were then selected and expanded. The expression of FLAG-tagged g2 was induced by adding 1 µg/ml tetracycline for 40 hours, and expression detected using immunofluorescence microscopy and
Western blot using anti-FLAG antibodies.
Culture of wild-type and R531G AMPK-γ2 HEK-293 cells and cell treatments
HEK-293 cells expressing wild-type or R531G AMPK-γ2 were generated as described (17).
T-Rex-Flp-In HEK-293 cells (Invitrogen) containing a single FRT site were cultured in
100 IU/ml penicillin, 100 µg/ml streptomycin, 15 µg/ml blasticidin and 100 µg/ml zeocin.
After transfection, T-Rex-Flp-In HEK-293 cells stably expressing either WT or R531G
AMPK-γ2 were cultured as above except that zeocin was replaced by 200 µg/ml hygromycin B. Forty hours after the induction of protein, 3 µM MTX/DMSO was added to cells for 16 hours, followed by 1 hour of AICAR in different concentrations.
AMPK activity assays
Wild-type HEK-293 cells or RG cells were assayed for AMPK activity as described (17) .
Activity of the purified rat liver AMPK, which is approximately an equal mixture of the α1β1γ1 and α2β1γ1 heterotrimer (29) , was measured in the presence or absence of AMP or PP2C as described (30) .
Statistics
9
Results are presented as means±SEM or means±SD. Comparisons between multiple groups were performed using ANOVA, followed by Bonferroni's or Dunnett's post hoc test.
Student's t-test was used when two groups were compared. Statistical significance was established at P<0.05.
RESULTS
MTX promotes AMPK activation in cultured myotubes
To determine whether MTX modulates AMPK activation, L6 myotubes and primary human myotubes were exposed to 5 µM MTX and sub-threshold (0.2 mM) and/or maximally effective (2 mM) concentrations of AICAR (14, 
MTX promotes metabolic effects in skeletal muscle via AMPK activation
To investigate whether the augmented AICAR-stimulated ACC phosphorylation in MTX-treated myotubes translates into increased lipid utilization, palmitate oxidation was measured in L6 myotubes incubated with 5 µM MTX and/or AICAR (0.2 or 2 mM). While 0.2 mM AICAR alone failed to increase palmitate oxidation, treatment with 0.2 mM AICAR and MTX together stimulated palmitate oxidation in L6 myotubes ( Fig. 2A) .
We next examined whether AICAR-stimulated glucose uptake is augmented in L6 myotubes after exposure to 5 µM MTX (Fig. 2B ). Although exposure of L6 myotubes to 0.2 mM AICAR alone failed to stimulate glucose uptake, a combined treatment with 0.2 mM AICAR and MTX markedly elevated glucose uptake. MTX enhanced glucose uptake in myotubes treated with saturating concentration of AICAR (2 mM), indicating AICAR responsiveness was improved. Glucose transport was also determined in EDL and soleus muscle treated with 2 mM AICAR and/or 10 µM MTX (Fig. 2C) . MTX robustly augmented AICAR-stimulated glucose uptake in EDL muscle, underscoring the effect of MTX to potentiate AICAR responsiveness. Although soleus muscle was less responsive to AICAR, glucose uptake was elevated upon MTX and AICAR exposure. MTX treatment did not affect GLUT4 protein abundance or GLUT4 mRNA expression (data not shown).
MTX promotes AMPK activation through indirect mechanisms
To confirm that MTX treatment inhibited ATIC, ZMP content was measured in L6 cells exposed to 0.2 mM AICAR and/or 5 µM MTX. AICAR alone did not elevate ZMP content, indicative of the high ZMP turnover (Fig.3A) . However, a combined treatment with MTX and 0.2 mM AICAR robustly increased the ZMP:ATP ratio. MTX exposure suppresses de novo purine synthesis (31) and may provoke ATP depletion in some situations (32, 33) .
ATP depletion decreases adenylate energy charge (Table 1) , which stimulates AMPK activation directly (34) . Given that the AMP concentration in cultured myotubes was too low for reliable quantitative estimation of energy charge, we determined the ADP:ATP ratio as a marker of cellular energy status (17) . MTX exposure, in the absence or presence of AICAR, increased the ADP:ATP ratio 24-28% (Fig. 3B) , indicating a modest degree of energy stress.
The observed increases in the ZMP content and the ADP:ATP ratio provide evidence that MTX promotes AMPK activation in cultured myotubes primarily by decreasing ZMP clearance, although ATP depletion may play a secondary role.
To establish a causal link between MTX-induced alterations in cellular nucleotide content and AMPK activation, wild-type HEK-293 and mutant HEK-293 (RG) cell lines were exposed to MTX (3 µM) and different concentrations of AICAR ( Fig. 3C-F) . RG cells harbor a single substitution (R531G) within the AMPK-γ2 subunit, which renders AMPK insensitive to stimulation by AMP and ZMP (17) . Both ZMP content and the ADP:ATP ratio were increased in wild-type cells treated with MTX and AICAR (Fig. 3C, D) . The elevated ZMP content during MTX and AICAR treatment was paralleled by an increase in AMPK activity (Fig. 3E) . Notably, MTX alone was sufficient to activate AMPK in wild-type cells.
However, the increase in AMPK activity was almost entirely abrogated in RG cells during co-incubation with MTX and AICAR (Fig. 3F) 
MTX is not a direct AMPK activator
To evaluate whether MTX activates AMPK allosterically, the activity of AMPK, purified from rat liver, was measured during incubation with AMP and/or increasing concentrations of MTX ( 
MTX is dependent on AMPK to promote lipid oxidation
Our results have established that MTX enhances AICAR action in skeletal muscle. To determine whether MTX depends on AMPK to promote metabolic alterations in skeletal muscle, we studied EDL and soleus muscles from wild-type and AMPK-γ3 -/-knock-out mice.
Isolated EDL and soleus muscles were incubated in the absence or presence of 10 µM MTX and/or a sub-threshold concentration of AICAR (0.2 mM). Treatment with 0.2 mM AICAR and MTX was sufficient to markedly stimulate AMPK activation and palmitate oxidation in wild-type EDL and soleus muscles (Fig. 5) . However, co-incubation with MTX and 0.2 mM AICAR did not stimulate phosphorylation of AMPK (Fig. 5A) and ACC (Fig. 5C ) in AMPK-γ3 -/-EDL muscle. MTX also failed to enhance AICAR-stimulated palmitate oxidation in AMPK-γ3 -/-EDL muscle (Fig. 5E ), supporting the notion that MTX promotes these metabolic alterations through AMPK. Due to low expression of AMPK-γ3 in wild-type soleus muscle (36) , the response to a combined treatment with MTX and 0.2 mM AICAR was similar between soleus muscles from wild-type and AMPK-γ3 -/-mice (Fig. 5B, D, F) .
To establish whether MTX promotes AMPK activation by decreasing ZMP clearance, nucleotide content was measured. ZMP content was markedly elevated upon addition of AICAR in wild-type EDL and soleus muscle ( 
Suppression of ATIC directly promotes AMPK activation and increases lipid oxidation
L6 myotubes were utilized to validate ATIC as an MTX target (Fig. 6A) . Expression of ATIC was suppressed in L6 myotubes using siRNA (Fig. 6B) . Exposure of myotubes transfected with scrambled siRNA to 0.2 mM AICAR did not increase ZMP content (Fig.   6C ). Conversely, stimulation with 0.2 mM AICAR robustly elevated ZMP content in ATICdepleted myotubes (Fig. 6C) , indicating diminished ZMP clearance. The ADP:ATP ratio was also elevated 12-15% in ATIC-depleted cells (Fig. 6D) , possibly reflecting purine depletion due to decreased de novo synthesis. The increased ZMP content in ATIC-depleted myotubes treated with AICAR increased AMPK and ACC phosphorylation and palmitate oxidation ( Fig. 6E-G) , consistent with the hypothesis that decreased ZMP clearance promotes AMPK activation. Notably, ATIC depletion alone increased AMPK phosphorylation and palmitate oxidation (Fig. 6E, G) , underscoring the link between ATIC suppression and AMPK activation in skeletal muscle.
Gene silencing suppressed ATIC expression 70% (Fig. 6B) . To test whether inhibition of residual ATIC activity provides an additional stimulus for AMPK activation, L6 myotubes were transfected with siRNA and subsequently exposed to MTX and incubated in the presence of 0.2 mM AICAR. In ATIC-depleted myotubes, MTX robustly stimulated AMPK and ACC phosphorylation, as well as palmitate oxidation (Fig. 6H-J These results highlight a role for AMPK as link between MTX and skeletal muscle energy metabolism.
Pharmacological activation of AMPK in skeletal muscle represents a promising strategy to bypass insulin-resistant pathways, in order to stimulate glucose uptake and improve insulin sensitivity in type 2 diabetes (19) . However, the search for peripheral AMPK activators has been challenging. AMPK activators, such as A-769662, target AMPK-β1
complexes that are poorly expressed in skeletal muscle (37, 38) , whereas AICAR has clinical limitations due to its poor bioavailability (18, 26) . Even with intravenous infusion, the plasma 15 concentration of AICAR (0.16-0.18 mM) remains below the threshold for AMPK activation in skeletal muscle (27, 39) . Here we report co-incubation with 0.2 mM AICAR and MTX activates AMPK and stimulates glucose uptake and lipid oxidation in skeletal muscle. These results are consistent with effects of MTX on AICAR in cancer cells (32) . Thus, combined therapy with MTX and AICAR might provide a novel pharmacological strategy to overcome current limitations of AICAR mono-therapy.
AMPK-γ3 is the muscle-specific isoform of the AMP-and ZMP-sensitive AMPK-γ subunit, which exists in three isoforms (γ1-γ3) (40), and a major isoform involved in exerciseinduced AMPK activation (41) . Although AMPK-γ3 is expressed primarily in glycolytic muscles (28, 36) , a complete failure of MTX to enhance AICAR action in AMPK-γ3 -/-EDL muscle was unexpected since AMPK-γ1 and -γ2 isoforms are also expressed (36) . 
